Introduction
Since ancient times humanity has depended on the diversity of plant resources for food, clothing, shelter, and traditional medicine to cure myriads of ailments. Early humans recognized their dependence on nature in both health and illness. Physical evidence of the use of herbal remedies has been found some 60,000 years ago in a burial site of a Neanderthal man uncovered in 1960 in a cave in northern Iraq. Here, scientists found great quantities of plant pollen, some of which came from medicinal plants still used today. The first written records detailing the use of herbs in the treatment of illness are in the form of Mesopotamian clay tablet writings and Egyptian papyrus. Led by instinct, taste and experience, primitive men and women treated illness by using plants, animal parts, and minerals that were not part of their usual diet. Primitive people learned by trial and error to distinguish useful plants with beneficial effects from those that were toxic or non-active, and also which combinations or processing methods had to be used to gain consistent and optimal results. Even in ancient cultures, tribal people methodically collected information on herbs and developed well-defined herbal pharmacopeias. Traditional medicine evolved over centuries, depending on local flora, culture, and religion. Nature has been a source of medicinal agents for thousands of years, and an impressive number of modern drugs have been isolated from natural sources, particularly plants and with many based on their use in traditional medicine. By using medicinal chemistry and combinatorial chemical and biosynthetic technology, novel natural product leads will be optimized on the basis of their biological activities to yield effective chemotherapeutic and other bioactive agents (Cragg et. al. 2005) . During the past decades, public interest in natural therapies, namely herbal medicine, has increased dramatically not only in developing countries but mainly in industrialized countries (Calixto, 2000) . The market for ayurvedic medicines is estimated to be expanding at 20% annually. Sales of medicinal plants have grown by nearly 25% in India during 1987-96, the highest rate of growth in the world. The global trade in medicinal plants is of the Fig. 1 . Annual CAM publications related to allergy and immunology. The numbers of articles published and available for search through PubMed using the search terms complementary medicine and immunology, asthma, allergy, autoimmune, hypersensitivity, or inflammation are shown.
Since the inception of the National Centre for Complementary and Alternative Medicine, there has been an enormous increase in the number of basic science and therapy-based clinical trials exploring CAM. The subspecialty of allergy and immunology represents a particularly fertile area with a large number of CAM therapies that have been shown to affect the immune system. Research has shown that phytoconstituents such as resveratrol, quercetin, and magnolol may affect transcription factors such as nuclear factor-kB and the signal transducer and activator of transcription/Janus kinase pathways with resultant changes in cytokines and inflammatory mediators. Clinically, there have been hundreds of trials looking at the effect of CAM on asthma, allergic rhinitis, and atopic dermatitis.
Bronchitis and related diseases
Bronchitis is described as the inflammation of the bronchial tubes (inflammation = itis). The inflammation causes swelling of the lining of these breathing tubes, narrowing the tubes and promoting secretion of inflammatory fluid. Bronchiolitis is a term that describes inflammation of the smaller bronchi referred to as bronchioles. In infants, this is usually caused by respiratory syncytial viruses (RSV) and affects the small bronchi and bronchioles more than the large. In adults, other viruses as well as some bacteria can cause bronchiolitis and often manifest as persistent cough and at times production of small plugs of mucus. Acute bronchitis describes the inflammation of the bronchi usually caused by a viral infection, although bacteria and chemicals may also cause acute bronchitis. Acute bronchitis is a cough that begins suddenly, usually due to a viral infection involving the larger airways. Colds (also known as viral upper airway infections) often involve the throat (pharyngitis) and nasal passages, and at times the larynx (resulting in a diminished hoarse voice, also known as laryngitis). Symptoms can include a runny nose, nasal stuffiness, and sore throat. Croup usually occurs in infants and young children and involves the voice box and upper large airways (the trachea and large bronchi). Chronic bronchitis for research purposes is defined as a daily cough with sputum production for at least three months, two years in a row. Chronic bronchitis is a diagnosis usually made on the basis of clinical findings of a long term persistent cough usually associated with tobacco abuse. From a pathologic standpoint, characteristic microscopic findings involving inflammatory cells seen in airway tissue samples make the diagnosis. When referring to pulmonary function testing, a decrease in the ratio of the volume of airflow at 1 second when compared to total airflow is less than 70%. This confirms the presence of obstructive airways disease of which chronic bronchitis is one type. Certain findings can be seen on imaging studies (chest X-ray, and CT or MRI of the lungs) to suggest the presence of chronic bronchitis; usually this involves an appearance of thickened tubes. Asthma: Asthma is a chronic inflammatory disease that affects about 300 million people worldwide, a total that is expected to rise to about 400 million over the next 15-20 years. Most asthmatic individuals respond well to the currently available treatments of inhaled corticosteroids and β-adrenergic agonists; however, 5-10% has severe disease that responds poorly. Asthma is a life threatening respiratory condition that causes: 1. The lining of the airways to become swollen 2. The body produces thick mucous 
Bronchodilator activity of two combined component of alkaloidal fraction of Ailanthus excelsa Roxb
Asthma is a chronic inflammatory disease that affects about 300 million people worldwide, a total that is expected to rise to about 400 million over the next 15-20 years (Kumar et al., 2010 a ) Ailanthus is a deciduous tree belonging to the family Simarubaceae, and widely distributed in Asia and North Australia. Commonly it is known as a Plant of Heaven. The bark of this plant is used as an anthelminthic, expectorant, antiasthmic, antispasmodic and antipyretic (Kumar et al., 2010 b ). Ailanthus excelsa is reported to be useful in a many ailments like asthma, allergy, bronchoconstriction etc. In the present study two combined Component of alkaloidal fraction of stem bark of Ailanthus excelsa Roxb.(AFAE) was for the first time evaluated for its bronchodilator activity. . A voucher specimen -899 was authenticated. Stem barks were dried, powdered, passed through 40 mesh sieve. The powdered material was extracted with methanol (95%) using soxhlet apparatus (10%). The brown extract (2gm) of stem bark of Ailanthus excelsa roxb. was used to prepare an alkaloidal rich fraction. The alkaloidal fraction was 500 mg and this Alkaloidal fraction was subjected to column chromatography for isolation of pure constituents using different polarity solvent and silica (60-120) as adsorbent. The component was isolated in chloroform: methanol (4:1) proportion (50 mg) and the same was checked for its purity by performing TLC in Beznene: methanol (4:1) solvent system. A single spot with Rf value of 0.56 was recorded. The isolated sample was then subjected to GC-MS which however showed the same to be a mixure of two components having close resemblance to each other and the fragmentation pattern was almost same and the retention time gap was very small. The molecular weights were 413 and 429. Alkaoidal tests were positive for the constituents. Animal: Albino rats (Wistar strain) and mice (musmusculus strain) of either sex weighing 150-200gm rats and 20-25gm mice respectively were used. They were housed in microlon boxes with standard laboratory diet and water ad libitum. The study was conducted after obtaining Institutional Animal Ethical Committee clearance (198/99/CPCSEA). Acute toxicity studies: AFAE was safe upto 1000mg/kg and based on the results of preliminary toxicity testing the doses of 10, 20 and 40mg/kg p.o were chosen for further experiments.
Bronchodilator activity
Effect of test drug on isolated goat trachea chain preparation: Isolated adult Goat tracheal tissue was obtained immediately after slaughter of the animals. Trachea was cut into individual rings and tied together in series to form a chain. Trachea was suspended in bath of Kreb's solution which was continuously aerated and maintained at 37 ± 0.5 ºC. Tissue was allowed to equilibrate for 45 min. under a load of 400 mg. A dose response curve for histamine was taken in variant molar concentrations, by maintaining 15 min time cycle. After obtaining a dose response curve of histamine on trachea, the AFAE was added to the respective reservoir and same doses of histamine were repeated. Graph of percentage of maximum contractile response on ordinate and negative logarithm of molar concentration of histamine on abscissa were plotted to record dose response curve of histamine, in absence and in presence AFAE (Bhujbal et al., 2009 ).
Milk induced leukocytosis and eosinophilia:
Mice were divided into five groups, six animals in each group. Animals belonging to group-I received distilled water (DW) 10 ml/kg, (p.o.). Animals belonging to group II, III, IV, V received boiled and cooled milk injection in dose of 4 ml/kg, (s.c.). Animals belonging to groups III, IV and V received AFAE in dose 10, 20 and 400 mg/kg, p. o. respectively, 1 hr before milk injection. Blood samples were collected from each mouse from the retro orbital plexus, under light ether anaesthesia. Total leukocyte count and total eosinophilia count was done in each group before drug administration and 24 hr after milk injection. Difference in Total leukocyte count and total eosinophilia count before and 24hr after drug administration was calculated.
Clonidine-induced Mast Cell Degranulation:
Rats were divided into five groups, six animals in each group. Animals belonging to group-I received vehicles 5 ml/kg, (p.o.) Animals belonging to group-II received Sodium cromoglycate 50 mg/kg, (i.p.). Animals belonging to group-III, IV and V received AFAE in dose (10, 20 and 40mg/kg, p.o.) respectively. The treatment was continued for 7 days. On day 7 th , 2 hour after the assigned treatment mast cells were collected from the peritoneal cavity. 10 ml of normal saline solution was injected into peritoneal cavity and abdomen was gently massaged for 90 second. The peritoneal cavity was carefully opened and the fluid containing mast cells was aspirated and collected in siliconised test tube containing 7 to 10 ml of RPMI-1640 Medium (pH 7.2-7.4). The mast cells were then washed thrice by centrifugation at low speed (400-500 rpm) and the pallet of mast cells were taken in the medium. The mast cells suspension approximately (1 x 10 6 cells/ml) was challenged with 0.5 µg/ml of clonidine solution and stained with 1 % toluidine blue and observed under high power microscope field (400 X). Total 100 cells were counted from different visual areas and the number of intact and degranulated cells was counted. The percent protection was calculated . Bronchoalveolar lavage and lung histology in rats: Animals were divided into five groups each group containing six animals. All the animals were sensitized by an intraperitoneal injection of 1ml alum precipitate antigen containing 20µg of ovaalbumin and 8mg of alum suspended in 0.9% sodium chloride solution. A booster injection of this alum-ovalbumin mixture was given 7 days later. Non sensitized animals were injected with alum only. Seven days after (15 th day) second injection animals were exposed to aerosolized ovaalbumin(1%) for 30 min. Standard & test group was received Dexamethasone (1mg/kg, i.p.) as standard and AFAE 10, 20, 40mg/kg as test drug, 5 hr before antigen challenge. The rats were sacrificed at the end of study (24 hr after sensitization) and tracheal catheter was inserted in trachea. Bronchoalveolar lavage fluid was collected by lavaging the lung with 2 aquilots of 5 ml of 0.9% sodium chloride solution total recovery volume per rat was approximately 8ml. Total leukocytes and eosinophiles, neutrophiles were counted under microscope and Histopathological evaluation of lung tissue was carried out (Kumar et al, 2010 c ).
Statistical analysis
All values were expressed as mean± S.E.M. and data were analysed by ANOVAs followed by dennest. 
Results

Bronchodilator activity: In vitro
Effect of AFEA (30µg/ml) on Histamine induced contraction of isolated goat tracheal chain preparation: In the present study, it was observed that AFAE inhibits the contraction produced by histamine in these tissue preparations. Histamine (10µg/ml) was taken in different dose level and DRC was plotted in absence and in presence of Ailanthus excelsa extract. Study showed that AFAE inhibits significantly (*p<0.05, **p<0.01, ***p<0.001) percentage contraction at concentration 30µg/ml in goat tracheal chain preparation. Dose dependent response relationship was seen (Figure 8 ). 
In -vivo
Milk induced leukocytosis and eosinophilia: Subcutaneous injection of milk at dose of 4 ml/kg produced a significant (***p< 0.001) increase in the leucocytes and eosinophiles count after 24 hr of its administration. In the groups of mice pretreated with AFAE at dose (10 mg/kg, 20 mg/kg and 40 mg/kg, p.o.), there was significant (*p<0.05, **p<0.01) inhibition of milk-induced Leucocytosis and eosinophilia (Figure 9 & 10). n= 6, values are expressed in mean±SEM. Control = Vehicle (10 ml/kg, p.o.). Intox. = milk 4 ml/kg, ***p<0.001, Intox. group compared with control group using student't, test and *p< 0.05, **p<0.01, AFAE compared to intox. Group using Statistical analysis done by ANOVA followed by Dunnet's test. Fig. 9 . Effect of AFAE on TLC count n= 6, values are expressed in mean±SEM. Control = Vehicle (10 ml/kg, p.o.). Intox. = milk 4 ml/kg, ***p<0.001, Intox. group compared with control group using student't, test and *p< 0.05, **p<0.01, AFAE compared to intox. Group using Statistical analysis done by ANOVA followed by Dunnet's test.
Fig. 10. Effect of AFAE on TEC
Effect of AFAE on clonidine-induced mast cell degranulation in rats: Clonidine induced mast cell degranulation was significantly (**p<0.01) inhibited by sodium cromoglycate (50 mg/kg, i.p.) and percent protection was found to be 68.42%. In the groups pre-treated AFAE (10, 20, 40 mg/kg, p.o) there was significant protection (**p< 0.01) of mast cells and the percent protection was 37.89, 54.21, and 61.42 % respectively (Figure 11 ). n= 6, values are expressed in mean±SEM. Control = Distilled water (5 ml/kg, p.o.). Std. = Sodium cromoglycate (50 mg/kg, i.p.), Std., AFAE10, AFAE20, AFAE40 compared with Control (ANOVA followed by Dunnett's test), **p < 0.01.
Fig. 11. Effect of AFAE on Clonidine-induced Mast cell Degranulation in rats
Effect of AFAE on Bronchoalveolar lavage in rats: Persistent mucosal airway inflammation, associated with an increase in T helper type 2 (Th2) cytokine levels, eosinophil infiltration into the airways, and mucus and immunoglobulin (IgE) production, are the main features of allergic asthma. The infiltration of cells like eosinophils, neutrophils, monocytes, macrophages, lymphocytes, etc., increases the allergic asthmatic effect. Injection of ovalbumin 20 µg + 8 mg alum in 1 ml (i.p.) on days 1 and 7 and 1% OVA aerosol on 15th day produced a significant (***P < 0.001) increase in the TLC. In the groups pretreated with standard drug dexamethasone (1 mg/kg i.p.), there was a significant (**P < 0.01) inhibition of ovalbumin-induced TLC and differential leukocyte count. The AFAE at doses of 10, 20, and 40mg/kg showed significant decrease in TLC and neutrophils, lymphocytes and monocytes, macrophages and eosinophils (*P < 0.05, **P < 0.01 [ (Figure 12 ). 
Discussion
The role of plants serving as purifiers of air has been known to us, since times immemorial.
To cope with the gradually increasing levels of toxic pollutants, tree plantation programs have been undertaken in different countries of the world to help in environmental cleanup. Ailanthus excelsa Roxb. (Simaroubaceae) is one such exotic avenue tree, the plantation of which has been encouraged under social forestry programs for large-scale tree plantation in different densely populated cities and towns of India [Mondal et al., 2007] . Histamine contracts the tracheobronchial muscle of guinea pig, goat, horse, dog and man. Goat tracheal chain is easier to handle and to prepare; it is also much more sensitive than guinea pig tracheal chain. Therefore, the dose relative contractile responses of different agonists like ACh, histamine, 5hydroxytryptamine and bradykinin can be observed in isolated goat trachea. In the present study the isolated goat tracheal chain preparation; there is right side shift of Dose Response Curve (DRC) of histamine in the presence of AFAE indicating Bronchodilation [Bhujbal et al., 2009] . In the rat mast cell granules, the histamine concentration has been calculated to be around 0.3 M. Both clonidine and compound 48/80 act through the dynamic expulsion of granules without causing any damage to the cell wall. Clonidine releases histamine from mast cells in a similar manner to a selective liberator like compound 48/80 [Lakdawala et al., 1980] . It is known that sodium cromoglycate; a standard mast cell stabilizer prevents degranulation of mast cells by raising the cyclic adenosine monophosphate. It has been known that all pharmacological agents that increase intracellular levels of cAMP relax airway smooth muscle and inhibit the release of autocoids from the tissue and basophils. The groups of animals pre-treated with AFAE resulted in a significant reduction in degranulation of mast cells and offered significant protection when challenged with clonidine indicating mast cell stabilizing activity which ultimately produces bronchodilation. The inflammatory response is characterized by an increase in the numbers of eosinophils and mast cells, mucus hypersecretion, and activation of T cells. Several studies have shown that T-helper type (Th2) cells play a major role in the initiation and maintenance of allergic airway inflammation and asthma through their increased production of Th2-type cytokines (IL-4, IL-5, and IL-13). These inflammatory cytokines also produced in the bronchial tissue by mast cells, alveolar macrophages, and epithelial cells, play a significant role in the pathogenesis of airway inflammation. The inflammatory mediators produce bronchoconstriction and the PAE helps to reduce the mediator which leads to bronchodilation. Ovalbumin increases the neutrophils, eosinophils, macrophages, monocytes, leukocytes, lymphocytes, epithelial cells, mucus etc., in BALF and AFAE helps to reduce all the allergic factors [Kumar ett al., 2010c] . Thus, it can be concluded from the results obtained in the present investigation that AFAE possesses significant bronchodilating activity. Hence, further detailed study needs to be conducted to separate the constituents and individually evaluate these phytoconstituent responsible to produce the above result and their clinical efficacy in the treatment of asthmatic patients.
